Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
JNCE.US
id: 608

$JNCE & $GMED M&A Case

  • #JounceTherapeutics, Inc. and #RedxPharma announced an all-share merger.
  • $JNCE shareholders will own approximately 37% in the new Co.
  • #Investors suspect that the pricing terms of the $JNCE & $REDX M&A deal are #unfair.
On February 2023, cancer treatment-focused Jounce Therapeutics, Inc. (JNCE) and British pharmaceutical company Redx Pharma (REDX) announced their plans for an all-share merger, which will result in the formation of a new entity known as Redx Inc. and its leadership will be headed by current Redx CEO Lisa Anson.
  • Under the terms of the merger agreement, Redx shareholders will receive 0.2105 Jounce shares for each Redx share. However, if Jounce approves the reverse stock split, the exchange rate will be adjusted to 0.0421 Jounce shares for each Redx share.
  • After the deal is completed, which is projected to take place in the second quarter, $REDX shareholders are expected to own approximately 63% of Redx Inc., while $JNCE shareholders will own approximately 37%.
Investors of #Jounce may have reasons to suspect that the pricing terms of the M&A transaction are unfair and that the Company BoD breached fiduciary duties to shareholders.
Case Status
Attorney Investigation
Alleged Offence
Mismanagement
Financial Misrepresentation
Failure to Disclose
Malpractice
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Shareholder
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
09 March 2023
Collecting participants…

Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase ...

    Ticker
    JNCE.US
    ISIN
    US4811161011
    CIK
    1640455
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    780 Memorial Drive, Cambridge, MA, United States, 02139